IPSC

Century Therapeutics Inc (IPSC) | Rumor.io

Century Therapeutics

IPSC

Attention (50-day avg)0%

Attention rank (50-day avg)#2,358

Bullish sentiment (50-day avg)89%

Price to earnings ratio-11.9

Market capitalization302.4M

Earnings per share-0.93

Dividend yield (TTM)—

Revenue (annual)109.2M

Net income (annual)-9.6M

Social

What share of all stock conversation is about IPSC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Mar 9

Century Therapeutics, Inc. ($IPSC) is advancing a pipeline of induced pluripotent stem cell-derived cell therapies to address autoimmune diseases and cancer.
The company's stock has been strong, reaching a new 52-week high, and is expected to continue growing with human data for its 813 program expected within the next 18 months.
Japan has approved $IPSC's Parkinson's disease treatment, and other stem-cell treatments for severe heart failure, with therapies expected to reach patients within months.

Generated by AI

Sentiment

Of the messages about IPSC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +11.9	84.57% +17.5
Bearish	—	—	0% -11.9	15.43% -17.5

Jan 8

Century Therapeutics, Inc. ($IPSC) has secured a $135M private placement financing to support its lead program CNTY-813, a potentially curative therapy for Type 1 Diabetes.
The company's market capitalization is now on par with that of Sana Biotechnology ($SANA), suggesting significant upside potential.
The recent price surge in $IPSC is attributed to the oversubscribed private placement financing, which is expected to drive the stock even higher.

Generated by AI

Topics

Of the messages about IPSC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	57.27%
Technical Analysis	—	—	0%	28.74%
Analysts	—	—	0%	4.7%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	9.29%

Analysts· Jul 13

Century Therapeutics ($IPSC) initiated with Overweight ratings by Piper Sandler ($38 PT), JP Morgan ($40 PT), and BofA Securities ($34 PT).
SVB Leerink initiated coverage on Century Therapeutics with an Outperform rating and a $33 price target.
Multiple analysts have initiated coverage on Century Therapeutics, including Edward Tenthoff at Piper Sandler, Eric Joseph at JP Morgan, and Geoff Meacham at BofA Securities.

Announcements· Jan 8

Century Therapeutics, Inc. ($IPSC) secured an oversubscribed $135M private placement financing to support its lead program, CNTY-813, a potentially curative therapy for Type 1 Diabetes.
The financing was led by new investor TCGX and included participation from several existing and new investors, with investors purchasing shares at $1.15 per unit and warrants at $2.60.
The private placement is expected to support the development of CNTY-813, a potentially curative therapy for Type 1 Diabetes, and is seen as a bullish development for the company.

Generated by AI

Community

Of the messages about IPSC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	94.37%	61.09%
Newcomers	0%	0%	5.63%	38.91%

Regulars· Jan 8

$IPSC has secured an oversubscribed $135 million private placement financing to support its lead program CNTY-813, a potentially curative therapy for Type 1 Diabetes.
The financing is led by new investor TCGX, and includes participation from several established healthcare capital firms, which may indicate a high level of confidence in the company's prospects.
The regulars are bullish on $IPSC's potential for significant upside, with some predicting a 100% or more gain in the stock price, citing the company's minimal short interest and the typically positive market reaction to such large private placements.

Newcomers· Jan 8

Century Therapeutics, Inc. ($IPSC) secured $135M in private placement financing to support its lead program, CNTY-813, a potentially curative therapy for Type 1 diabetes.
The recent surge in $IPSC stock is attributed to the announcement of the oversubscribed private placement financing, with some investors noting a parabolic candle and highest volume in months.
New investors are taking note of $IPSC's significant gain, with one user observing a 43% increase, and another noting the stock's volatility, advising to plan trades carefully.

Generated by AI

News

Century Therapeutics: Competitors May Be Quietly De-Risking Its Biggest Bet (NASDAQ:IPSC)

Century Therapeutics' CNTY-813 aims to deliver insulin-producing islets without chronic systemic immunosuppression. Find out why IPSC stock is a buy.

2h agoSeeking Alpha

Century Therapeutics SVP Douglas Carr sells $3,199 in shares

14d agoInvesting.com

Century Therapeutics CTO Gregory Russotti sells $4,992 in stock

14d agoInvesting.com

Century Therapeutics Adds Director, Advances Cell Therapy Pipeline

Detailed price information for Century Therapeutics Inc (IPSC-Q) from The Globe and Mail including charting and trades.

19d agoThe Globe and Mail

Century Therapeutics SVP sells $520 in stock for tax withholding

20d agoInvesting.com

Century Therapeutics appoints Joseph Truitt to board

20d agoInvesting.com

Also Discussed

Investors talking about IPSC also mention

#	Name	Attention
1	Caribou Biosciences, Inc.CRBU	0%new
2	Fate Therapeutics Inc.FATE	0%new
3	Sana Biotechnology Inc.SANA	0%0
4	VERV - Verve Therapeutics, Inc.	——
5	Beam Therapeutics IncBEAM	0.02%+0.02
6	Prime Medicine, Inc.PRME	0%-0.01
7	PSTX - Poseida Therapeutics, Inc.	——
8	Precision BioSciences, Inc.DTIL	0%new
9	Zentalis Pharmaceuticals, Inc.ZNTL	0%new
10	Autolus Therapeutics plc ADRAUTL	0%+0

Century Therapeutics Inc

Healthcare
Biotechnology

Century Therapeutics Inc is a biotechnology company focused on developing allogeneic cell therapies for cancer, autoimmune diseases, and other immune-mediated conditions. The company uses induced pluripotent stem cell technology to create off-the-shelf immune cell products, including natural killer and T cell therapies designed to target solid tumors and hematological malignancies. Its current pipeline also includes programs in type 1 diabetes and other autoimmune applications, reflecting a broader effort to apply engineered cell therapy platforms across multiple disease areas. Century Therapeutics combines stem cell derivation, gene editing, and immune-evasion technologies to support scalable manufacturing and differentiated product development. Headquartered in Philadelphia, Pennsylvania, Century Therapeutics operates in the advanced biotechnology segment of the healthcare market, where it develops next-generation cellular medicines intended for clinical use.

Website

Location

25 North 38th Street

Philadelphia, PA, 19104

United States

Social

What share of all stock conversation is about IPSC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Mar 9

Century Therapeutics, Inc. ($IPSC) is advancing a pipeline of induced pluripotent stem cell-derived cell therapies to address autoimmune diseases and cancer.
The company's stock has been strong, reaching a new 52-week high, and is expected to continue growing with human data for its 813 program expected within the next 18 months.
Japan has approved $IPSC's Parkinson's disease treatment, and other stem-cell treatments for severe heart failure, with therapies expected to reach patients within months.

Generated by AI

Sentiment

Of the messages about IPSC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +11.9	84.57% +17.5
Bearish	—	—	0% -11.9	15.43% -17.5

Jan 8

Century Therapeutics, Inc. ($IPSC) has secured a $135M private placement financing to support its lead program CNTY-813, a potentially curative therapy for Type 1 Diabetes.
The company's market capitalization is now on par with that of Sana Biotechnology ($SANA), suggesting significant upside potential.
The recent price surge in $IPSC is attributed to the oversubscribed private placement financing, which is expected to drive the stock even higher.

Generated by AI

Topics

Of the messages about IPSC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	57.27%
Technical Analysis	—	—	0%	28.74%
Analysts	—	—	0%	4.7%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	9.29%

Analysts· Jul 13

Century Therapeutics ($IPSC) initiated with Overweight ratings by Piper Sandler ($38 PT), JP Morgan ($40 PT), and BofA Securities ($34 PT).
SVB Leerink initiated coverage on Century Therapeutics with an Outperform rating and a $33 price target.
Multiple analysts have initiated coverage on Century Therapeutics, including Edward Tenthoff at Piper Sandler, Eric Joseph at JP Morgan, and Geoff Meacham at BofA Securities.

Announcements· Jan 8

Century Therapeutics, Inc. ($IPSC) secured an oversubscribed $135M private placement financing to support its lead program, CNTY-813, a potentially curative therapy for Type 1 Diabetes.
The financing was led by new investor TCGX and included participation from several existing and new investors, with investors purchasing shares at $1.15 per unit and warrants at $2.60.
The private placement is expected to support the development of CNTY-813, a potentially curative therapy for Type 1 Diabetes, and is seen as a bullish development for the company.

Generated by AI

Community

Of the messages about IPSC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	94.37%	61.09%
Newcomers	0%	0%	5.63%	38.91%

Regulars· Jan 8

$IPSC has secured an oversubscribed $135 million private placement financing to support its lead program CNTY-813, a potentially curative therapy for Type 1 Diabetes.
The financing is led by new investor TCGX, and includes participation from several established healthcare capital firms, which may indicate a high level of confidence in the company's prospects.
The regulars are bullish on $IPSC's potential for significant upside, with some predicting a 100% or more gain in the stock price, citing the company's minimal short interest and the typically positive market reaction to such large private placements.

Newcomers· Jan 8

Century Therapeutics, Inc. ($IPSC) secured $135M in private placement financing to support its lead program, CNTY-813, a potentially curative therapy for Type 1 diabetes.
The recent surge in $IPSC stock is attributed to the announcement of the oversubscribed private placement financing, with some investors noting a parabolic candle and highest volume in months.
New investors are taking note of $IPSC's significant gain, with one user observing a 43% increase, and another noting the stock's volatility, advising to plan trades carefully.

Generated by AI

Century Therapeutics

Social

Mar 9

Jan 8

Analysts· Jul 13

Announcements· Jan 8

Regulars· Jan 8

Newcomers· Jan 8

Century Therapeutics: Competitors May Be Quietly De-Risking Its Biggest Bet (NASDAQ:IPSC)

Century Therapeutics SVP Douglas Carr sells $3,199 in shares

Century Therapeutics CTO Gregory Russotti sells $4,992 in stock

Century Therapeutics Adds Director, Advances Cell Therapy Pipeline

Century Therapeutics SVP sells $520 in stock for tax withholding

Century Therapeutics appoints Joseph Truitt to board

Also Discussed

Century Therapeutics Inc

Company Information

Location

Century Therapeutics: Competitors May Be Quietly De-Risking Its Biggest Bet (NASDAQ:IPSC)

Century Therapeutics SVP Douglas Carr sells $3,199 in shares

Century Therapeutics CTO Gregory Russotti sells $4,992 in stock

Century Therapeutics Adds Director, Advances Cell Therapy Pipeline

Century Therapeutics SVP sells $520 in stock for tax withholding

Century Therapeutics appoints Joseph Truitt to board

Also Discussed

Social

Mar 9

Jan 8

Analysts· Jul 13

Announcements· Jan 8

Regulars· Jan 8

Newcomers· Jan 8